 aclaris Therapeutics (NASDAQ:ACRS ) reported third quarter 2018 net revenues of $1.6 million, which consisted of net sales of ESKATA of $0.5 million and contract research revenue of $1.1 million. 
 our net loss was $32.7 million for the third quarter of 2018 compared to $18.2 million for the third quarter of 2017, while our net loss was $94.2 million for the first 9 months of 2018 compared to $45.6 million in the first 9 months of 2017. during the third quarter of 2018, we launched a new treatment paradigm for patients with persistent facial erythema or redness, associated with rosacea in the form of the topical treatment of common warts or verruca vulgaris. 
 we also launched a new treatment paradigm for patients with patchy alopecia areata in the form of the topical treatment of alopecia totalis and alopecia universalis. 
 we also completed enrollment in the ongoing open-label extension study of the topical treatment of alopecia areata in patients with less severe disease, patchy disease versus slower regrowth in a patient with more severe disease. 